These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 24964696)

  • 1. Measurement of health outcomes.
    Thavorncharoensap M
    J Med Assoc Thai; 2014 May; 97 Suppl 5():S27-32. PubMed ID: 24964696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Measurement of clinical effects.
    Teerawattananon Y; Thavorncharoensap M; Mohara A
    J Med Assoc Thai; 2008 Jun; 91 Suppl 2():S38-42. PubMed ID: 19253486
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Budget impact analysis.
    Leelahavarong P
    J Med Assoc Thai; 2014 May; 97 Suppl 5():S65-71. PubMed ID: 24964701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Defining the scope of health technology assessment and types of health economic evaluation.
    Tanvejsilp P; Ngorsuraches S
    J Med Assoc Thai; 2014 May; 97 Suppl 5():S10-6. PubMed ID: 24964694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Guidelines for health technology assessment in Thailand (second edition)--the development process.
    Chaikledkaew U; Kittrongsiri K
    J Med Assoc Thai; 2014 May; 97 Suppl 5():S4-9. PubMed ID: 24964693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of surrogate outcomes in model-based cost-effectiveness analyses: a survey of UK Health Technology Assessment reports.
    Taylor RS; Elston J
    Health Technol Assess; 2009 Jan; 13(8):iii, ix-xi, 1-50. PubMed ID: 19203465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Presentation of economic evaluation results.
    Chaikledkaew U
    J Med Assoc Thai; 2014 May; 97 Suppl 5():S72-80. PubMed ID: 24964702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thai health technology assessment guideline development.
    Teerawattananon Y; Chaikledkaew U
    J Med Assoc Thai; 2008 Jun; 91 Suppl 2():S11-5. PubMed ID: 19253483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Measurement of costs.
    Riewpaiboon A
    J Med Assoc Thai; 2008 Jun; 91 Suppl 2():S28-37. PubMed ID: 19253485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health economics and outcomes research within drug development: challenges and opportunities for reimbursement and market access within biopharma research.
    van Nooten F; Holmstrom S; Green J; Wiklund I; Odeyemi IA; Wilcox TK
    Drug Discov Today; 2012 Jun; 17(11-12):615-22. PubMed ID: 22366662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Defining types of economic evaluation.
    Ngorsuraches S
    J Med Assoc Thai; 2008 Jun; 91 Suppl 2():S21-7. PubMed ID: 19255985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A review of cost-effectiveness evaluations as part of national health technology assessments of biologic DMARDs in the treatment of rheumatoid arthritis.
    Iannazzo S; De Francesco M; Gomez-Ulloa D; Benucci M
    Expert Rev Pharmacoecon Outcomes Res; 2013 Aug; 13(4):455-68. PubMed ID: 23977974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surrogate outcomes in health technology assessment: an international comparison.
    Velasco Garrido M; Mangiapane S
    Int J Technol Assess Health Care; 2009 Jul; 25(3):315-22. PubMed ID: 19619350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health system and equity perspectives in health technology assessment.
    Hanvoravongchai P
    J Med Assoc Thai; 2008 Jun; 91 Suppl 2():S74-87. PubMed ID: 19253490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Policy making and roles of health technology assessment.
    Tantivess S
    J Med Assoc Thai; 2008 Jun; 91 Suppl 2():S88-99. PubMed ID: 19253491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reviewing the evidence to inform the population of cost-effectiveness models within health technology assessments.
    Kaltenthaler E; Tappenden P; Paisley S
    Value Health; 2013; 16(5):830-6. PubMed ID: 23947977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Where are the limits of cost-effectiveness analysis and health technology assessment?
    Culyer AJ
    J Med Assoc Thai; 2014 May; 97 Suppl 5():S1-2. PubMed ID: 24964691
    [No Abstract]   [Full Text] [Related]  

  • 18. Use of surrogate outcomes in cost-effectiveness models: a review of United Kingdom health technology assessment reports.
    Elston J; Taylor RS
    Int J Technol Assess Health Care; 2009 Jan; 25(1):6-13. PubMed ID: 19126246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Handling time in economic evaluation studies.
    Permsuwan U; Guntawongwan K; Buddhawongsa P
    J Med Assoc Thai; 2014 May; 97 Suppl 5():S50-8. PubMed ID: 24964699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Measurement of clinical-effect: utility.
    Sakthong P
    J Med Assoc Thai; 2008 Jun; 91 Suppl 2():S43-52. PubMed ID: 19253487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.